Evaluation of long term safety of Adalimumab in patients with moderately to severely active UC [ Time Frame: 10 years observational period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Evaluation of long term effectiveness of Adalimumab in patients with moderately to severely active UC who have had an inadequate response to conventional therapy [ Time Frame: 10 years observational period ] [ Designated as safety issue: No ]

Patients who are being prescribed and treated with Immunomodulatory Therapy

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Sampling Method:

Probability Sample

Study Population

Adult patients with moderately to severely active Ulcerative Colitis (UC) who have been prescribed HUMIRA according to the local label and adult patients being prescribed and treated with IMM (6-mercaptopurine or azathioprine) with no concurrent biologic use.

Criteria

Inclusion Criteria:

For enrollment into the HUMIRA treatment group; adult patients with moderately to severely active UC who has been prescribed HUMIRA therapy according to the local product label and meets one of the following:

Is currently taking HUMIRA therapy and has received at least 8 weeks of therapy; OR

Is entering after participation in an Abbott or AbbVie sponsored UC study and; has received continuous HUMIRA therapy since initiation of therapy

For enrollment into the IMM treatment group; adult patients with moderately to severely active UC who has been prescribed IMM therapy, is currently taking IMM therapy, and has received at least 12 consecutive weeks of IMM therapy

Patients capable of and willing to grant authorization for use/disclosure of data being collected and provided to AbbVie and to comply with the requirements of the Registry protocol

Exclusion Criteria:

Patients who can not be treated with HUMIRA in accordance with the local label or cannot be treated with IMM therapy.

Patients who are being treated with any investigational agents and/or approved biologics other than Humira.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01848561